// App-Quantinova.ai

: Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Researchers

Presenter

  • Moshe Yair Levy

Principal Investigators

  • Lin Xie

  • Yuexi Wang

  • Frank Neumann

  • Shouryadeep Srivastava

  • Daniel Naranjo

  • Qisu Zhang

  • Mehul Dalal

Medical Centers

  • Baylor University Medical Center, Dallas, TX

  • STATinMED Research, Ann Arbor, MI

  • Millennium Pharmaceuticals, Inc., Cambridge, MA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic Myelogenous Leukemia

  • Myocardial infarction

  • Deep vein thrombosis

  • Pulmonary embolism

  • Intracerebral hemorrhage

  • Ischemic stroke

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved